Wechselwirkungen · Triumeq
Triumeq 50 mg/600 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 13
HOS-129272 · Präparat HOS-096703
Sorbitol Sorbitol solution (3.2 g, 10.2 g, Single dose lamivudine When possible, avoid chronic 13.4 g)/Lamivudine oral solution 300 mg coadministration of Triumeq with medicinal products containing sorbitol Lamivudine: or other osmotic acting poly-alcohols or AUC ↓ 14%; 32%; 36% monosaccharide alcohols (eg: xylitol, mannitol, lactitol, maltitol). Consider Cmax ↓ 28%; 52%, 55%. more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided. Potassium channel blockers Fampridine (also known as Fampridine ↑ Co-administration of dolutegravir has dalfampridine)/Dolutegravir the potential to cause seizures due to increased fampridine plasma concentration via inhibition of OCT2 transporter; co-administration has not been studied. Fampridine co- administration with Triumeq is contraindicated (see section 4.3). Antacids and supplements
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): maltitol (HOS-085849) xylitol (HOS-085846) dalfampridine (HOS-124191) mannitol (HOS-085847) lactitol (HOS-085848) potassium (HOS-086929) sorbitol (HOS-085845)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-15T14:46:00Z · SHA-256 b49ac3bee235cd6ac4023cc2bbeb8b80e01234448e4e420209ba281a1edf7209 · Passage 1e69963a06cb46bc20e212ed907227e0d44e3697e23d1ae35270ea2927f9d4a5 · Zeichen 22679–24574 im Abschnitt